Bioelectric Stimulator Modulating COL17A1 Expression for Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mutations in the human collagen XVII gene (COL17A1) lead to skin blistering and hair loss due to diminished epidermal adhesion and hair follicle stem cell aging, with existing treatments failing to effectively modulate protein expression for tissue regeneration and skin health.
Innovation Solution
A bioelectric stimulator that applies specific bioelectric signaling sequences to modulate COL17A1 expression, using frequencies such as 25 Hz for upregulation and 50 Hz or 75 Hz for downregulation, combined with growth factors like IGF-1 and VEGF to promote tissue regeneration and skin health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for COL17A1-related conditions, then treatment simplicity is maintained, but treatment effectiveness for tissue regeneration and skin health is insufficient
Solution Approach 1:
The patent applies parameter changes by using specific bioelectric signal parameters (frequency, voltage, pulse width) to modulate COL17A1 expression. Different frequencies (e.g., 25 Hz for upregulation, 50 Hz for downregulation) and voltages (10-100 mV) are used to achieve different therapeutic effects, transforming the treatment approach from conventional non-specific methods to precise parameter-controlled modulation.
Solution Approach 2:
The patent replaces conventional mechanical or chemical treatment systems with a bioelectric stimulation system. Instead of using physical manipulations or chemical compounds, the invention uses electrical signals to control protein expression, substituting a more precise and controllable energy form for traditional mechanical/chemical approaches.
2Reliability
If precise bioelectric signaling sequences are applied to modulate COL17A1 expression, then tissue regeneration and skin health are improved, but device complexity and treatment cost increase
Solution Approach 1:
The patent segments the treatment into distinct bioelectric signal protocols for different therapeutic goals. Specific frequency ranges and pulse patterns are segmented for different functions: 25 Hz for upregulation, 50-75 Hz for downregulation, with specific pulse widths and duty cycles. This segmentation allows the complex device to be programmed with modular, purpose-specific signal sequences.
Solution Approach 2:
The patent incorporates feedback mechanisms to monitor and adjust bioelectric signal delivery based on tissue response. The system can detect changes in tissue electrical properties and adjust stimulation parameters accordingly, ensuring optimal COL17A1 modulation while adapting to individual patient variations and treatment progression.
3Measurement precision
If high-frequency bioelectric signals are used for COL17A1 modulation, then protein expression control is enhanced, but energy consumption increases
Solution Approach 1:
The patent uses periodic action by applying pulsed bioelectric signals rather than continuous stimulation. The signals are delivered in controlled pulses with specific duty cycles (e.g., 50% duty cycle), allowing tissue recovery between pulses while maintaining effective modulation. This periodic delivery reduces overall energy consumption compared to continuous high-frequency stimulation.
Solution Approach 2:
The patent applies partial action by using moderate voltage levels (10-100 mV) that are sufficient to trigger COL17A1 modulation without excessive energy input. The treatment uses just enough stimulation to achieve the desired protein expression change, avoiding over-stimulation and associated energy waste.
Data Source
AI summary
Described is a low voltage, pulsed electrical stimulation device for controlling expression of Collagen Type XVII Alpha 1 chain (COL17A1), a useful protein, by tissues. Also described are methods of COL17A1 in cells.